指南
医学
肺癌
家庭医学
重症监护医学
医学诊断
临床肿瘤学
癌症
临床诊断
梅德林
替代医学
肺癌的治疗
临床实习
病历
医疗保健
临床研究
医疗
医学文献
中医药
癌症治疗
医学实验室
食品药品监督管理局
肺癌筛查
作者
Bing Zhang,R B Zhong,Hua Zhong
出处
期刊:PubMed
[National Institutes of Health]
日期:2025-10-23
卷期号:47 (10): 981-986
被引量:1
标识
DOI:10.3760/cma.j.cn112152-20250819-00408
摘要
The "Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)" was collaboratively completed under the leadership of Professor Han Baohui from the Department of Pulmonary and Critical Care Medicine at Shanghai Chest Hospital and Professor Wang Jie from the Department of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College. The guideline involved the cooperation of more than 50 lung cancer diagnosis and treatment institutions and over 100 experts across China. Since the completion of the first edition in 2018, the guideline is typically revised annually to promptly incorporate the latest advancements in the field of lung cancer. The most distinctive feature of these guidelines is that they exclusively reference the indications approved by the National Medical Products Administration of China. At the same time, particular emphasis is placed on integrating clinical research data from Chinese scholars based on Chinese patients, thereby enhancing the guidelines' authority, applicability, and drug accessibility. The "Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)" was officially published in September 2025. To better introduce the key points of the guidelines to peers, this interpretation has been prepared.
科研通智能强力驱动
Strongly Powered by AbleSci AI